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化动力学直径大小为 210 nm、表面电势为-33 mV、药物包封率为 92%、载药量
为 24%，其体外药物释放分为突释和缓释两阶段。丝裂霉素 C-磷脂复合物自组



























































Mitomycin C (MMC) is a kind of highly potent antibiotic with a wide 
anti-cancer spectrum extenisively used in clinic. However, MMC is subject to 
limitations associated with extremely low bioavailability, very short blood half-life, 
non-specific biodistribution, and severe side effects, thus the plasma MMC 
concentration at the tumor site is only one twentieth of MMC concentration of 
intravenous administration. Therefore, how to maximize the drug efficacy for killing 
tumor cells and minimize the side effects of drug is undoubtedly an important issue of 
the MMC in cancer therapy. In the present study, on the basis of self-assembly 
technique, we developed MMC-phospholipid complex based nanoscale single-drug 
delivery systems, and both MMC-phospholipid complex and methotrexate 
(MTX)-prodrug based nanoscale double-drugs delivery systems. The self-assemble 
behaviors, drug stability, drug-loading ability, drug release and pharmacokinetic 
behavior, as well as in vitro and in vivo drug efficacy of those drug delivery systems 
were systemically investigated. 
We prepared MMC-phospholipid complex to self-assemble into nanoparticles 
which were served as the MMC-loaded drug carriers. We proved the effective 
complexation between MMC and phospholipd using (
1
H) nuclear magnetic resonance 
(
1
H NMR), differential scanning calorimetry (DSC), x-ray diffraction (XRD), fourier 
transform infrared spectra (FTIR), transmission electron microscope (TEM), and 
high-performance liquid chromatography (HPLC). We further demonstrated that the 
electrostatic interaction and hydrogen-bonding interaction integrating and 
coordinating weak interactions acted an important role between MMC and 
phospholipid. The preparation of MMC-phospholipid complex was optimized by 
single-factor and orthogonal experiments, in which the complexation rate was up to 
95.6%. In addition, we investigated the physiochemical characteristics of 














light scattering (DLS), electrophoretic light scattering (SLS), scanning electron 
microscope (SEM), transmission electron microscope (TEM), and atomic force 
microscope (AFM). The self-assembled nanoparticles loaded with 
MMC-phospholipid complex had a liposome-like intact vesicle structure, a spherical 
shape, a hydrodynamic particle size of 210 nm, a zeta potential of -33 mV, drug 
encapsulation efficacy of 92%, drug-loading content of 24%, and a bi-phase drug 
release manner (initial burst drug release and subsequent sustained drug release). The 
MMC-phospholipid complex-loaded nanoparticles possessed the advantage over the 
MMC-loaded liposomes (drug-loading content of 7%) in drug-loading ability.  
Based on the MMC-phospholipid complex, we used reverse 
micelles-emulsification-solvent evaporation through hydrophilic-hydrophobic 
interaction-induced self-assembly to construct MMC-phospholipid complex-based, 
folate functionalized, and dual-controlled drug release polymer-lipid hybrid 
nanoparticles for a further intelligent controlled drug release, reduced drug burst 
release, and improved drug targeting effect. The advantage of this kind of drug 
delivery systems was that it could reduce the premature drug leakage and burst release 
(reduce the non-specific drug release) and increase the sustained and controlled drug 
release (increase the specific drug release). The MMC-phospholipid complex-based 
and folate functionalized polymer-lipid hybrid nanoparticles significantly enhanced 
the cellular uptake and cytotoxicity against HeLa cells, reduced the blood elimination 
rate and increased the bioavailability in SD rats, more importantly, and improved the 
antitumor effect while reducing the systemic adverse effect against tumor-bearing 
mice compared with free MMC. 
Based on the MMC-phospholipid complex-loaded polymer-lipid hybrid 
nanoparticles, we further synthetized 
1,2-distearoyl-snglycero-3-phosphoethanolamine-N-methotrexate(polyethylene glycol) 
(DSPE-PEG-MTX) and validated it using (
1





ultraviolet and visible absorption spectrum (UV-vis), fourier transform infrared 
spectra (FTIR), matrix-assisted laser desorption/ionization time of flight mass 














Then we used DSPE-PEG-MTX and MMC-phospholipid complex as self-assemble 
moties to controllably construct the novel self-targeted, both MMC and MTX 
drugs-loaded, multi-drugs-synergistically treated polymer-lipid hybrid nanoscaled 
drug delivery systems. The dual roles (targeting and anticancer) of DSPE-PEG-MTX 
as a functional self-assemble motif played a vital role in the multi-functionalization 
coordinated with highly simplification of the nanoscaled drug delivery systems. 
Another advantage of the systems was that both MMC and MTX could coordinate 
and cooperate the early-phase targeting effect (in blood circulation and tumor 
microenvironment) and late-phase synergistically anticancer effect (inside tumor 
cells). Compared with the free MMC, physical mixture MMC and MTX, and 
MMC-phospholipid complex-based and single drug-loaded polymer-lipid hybrid 
nanoparticles, the MMC-phospholipid complex-based and both drugs-loaded 
self-targeted polymer-lipid hybrid nanoparticles significantly enhanced the cellular 
uptake and cytotoxicity and realized the site-specific drug delivery to nucleus and 
cytoplasm and synergistic cytotoxicity against HeLa cells, reduced the blood 
elimination and proloned the blood half-life in SD rat, and synergistically enhanced 
the antitumor effect while decreasing the systemic toxicity against tumor-bearing 
nude mice. 
Keywords: self-assembly; mitomycin C-phospholipid complex; nanoscaled drug 
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